Banque Cantonale Vaudoise Lowers Position in The Clorox Company (NYSE:CLX)

Banque Cantonale Vaudoise lessened its holdings in shares of The Clorox Company (NYSE:CLXFree Report) by 36.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,982 shares of the company’s stock after selling 3,455 shares during the period. Banque Cantonale Vaudoise’s holdings in Clorox were worth $784,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. First Command Advisory Services Inc. purchased a new stake in shares of Clorox in the third quarter valued at approximately $124,000. PGGM Investments boosted its position in Clorox by 16.5% during the third quarter. PGGM Investments now owns 2,923 shares of the company’s stock worth $383,000 after purchasing an additional 413 shares in the last quarter. Amalgamated Bank boosted its position in Clorox by 4.2% during the third quarter. Amalgamated Bank now owns 34,907 shares of the company’s stock worth $4,575,000 after purchasing an additional 1,421 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Clorox during the third quarter worth $11,882,000. Finally, Bryn Mawr Capital Management LLC purchased a new stake in Clorox during the third quarter worth $490,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Clorox Stock Performance

Clorox stock opened at $154.79 on Wednesday. The firm has a market capitalization of $19.21 billion, a P/E ratio of 245.70, a PEG ratio of 2.31 and a beta of 0.43. The stock has a fifty day moving average price of $143.56 and a 200 day moving average price of $141.75. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $178.21. The company has a current ratio of 0.89, a quick ratio of 0.57 and a debt-to-equity ratio of 11.37.

Clorox (NYSE:CLXGet Free Report) last released its earnings results on Thursday, February 1st. The company reported $2.16 EPS for the quarter, beating the consensus estimate of $1.08 by $1.08. Clorox had a return on equity of 319.41% and a net margin of 1.09%. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the firm posted $0.98 earnings per share. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. Equities research analysts anticipate that The Clorox Company will post 5.63 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Shareholders of record on Wednesday, January 24th will be given a dividend of $1.20 per share. This represents a $4.80 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, January 23rd. Clorox’s dividend payout ratio (DPR) is presently 761.92%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. UBS Group boosted their target price on Clorox from $145.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Jefferies Financial Group started coverage on Clorox in a report on Monday, November 13th. They issued an “underperform” rating and a $117.00 price target for the company. DA Davidson reissued a “neutral” rating and issued a $162.00 price target on shares of Clorox in a report on Monday. Bank of America raised Clorox from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $120.00 to $150.00 in a report on Friday, December 15th. Finally, JPMorgan Chase & Co. boosted their price target on Clorox from $145.00 to $152.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. According to, Clorox has an average rating of “Hold” and an average target price of $144.64.

Check Out Our Latest Stock Report on Clorox

Clorox Company Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Read More

Want to see what other hedge funds are holding CLX? Visit to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with's FREE daily email newsletter.